An amyloid PET scan can clarify an uncertain Alzheimer's diagnosis and guide next steps in care, but it cannot diagnose Alzheimer's by itself. Its benefit is sharper decision-making in selected cases, while its limits include false reassurance or alarm if used for screening or severity grading. An amyloid PET scan is a brain imaging test for beta-amyloid plaques, a hallmark pathology of Alzheimer's disease. It injects a small amount of radioactive tracer that binds plaques, letting doctors estimate plaque density in a living brain alongside standard cognitive evaluation.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the scan measures
- When the scan is most useful
- What positive and negative results mean
- When to skip it and what to verify first
What the scan measures
The tracer makes amyloid plaques visible so specialists can estimate neuritic plaque density. The result supports clinical judgment rather than replacing it.
It is used with history, exams, cognitive testing, and often other workup. The Society of Nuclear Medicine and Molecular Imaging describes the test as an adjunct to standard evaluation in its appropriate-use criteria. Approved tracers for this use include florbetapir, flutemetamol, and florbetaben for adults with cognitive impairment being evaluated for Alzheimer's and other causes of decline, as described in the FDA approval letter.
When the scan is most useful
The clearest benefit is a sharper differential diagnosis and more targeted management. In the IDEAS study, amyloid PET changed physicians' diagnoses in over one-third of cases and altered management in about 60%, according to Being Patient.
Updated 2025 Alzheimer's Association and SNMMI criteria reserve the test for cases where Alzheimer's is suspected but remains uncertain after specialist evaluation and the result would change diagnosis, prognosis, or management. Practical examples include:.
- persistent unexplained mild cognitive impairment
- atypical symptoms that do not fit a classic pattern
- early-onset cognitive decline
- mixed presentations where more than one cause is possible
What positive and negative results mean
A negative scan means sparse to no neuritic plaques. That pattern is inconsistent with an Alzheimer's neuropathological diagnosis at scan time and substantially lowers the likelihood that impairment is due to Alzheimer's.
A positive scan shows moderate to frequent plaques, but it does not by itself establish Alzheimer's. Amyloid also occurs in cognitively normal older adults and other neurologic disorders and does not track dementia severity. A reader should therefore ask what the result changes: diagnosis, prognosis, referrals, safety planning, medications, or eligibility for anti-amyloid therapy.
When to skip it and what to verify first
The test is not appropriate for cognitively unimpaired screening. It is also not appropriate for typical late-onset Alzheimer's already meeting clinical criteria, testing based only on family history or ApoE-e4, substituting for genetic testing, grading severity, or nonmedical insurance, legal, or employment uses. Before scheduling, confirm the clinical question, the referring specialist, radiation and pregnancy or breastfeeding precautions for IV tracer, and coverage.
A positive result is generally required to confirm amyloid pathology before anti-amyloid therapy. Since CMS retired national restriction NCD 220.6.20 effective Oct. 13, 2023, regional contractors set coverage, so patients should verify authorization and out-of-pocket cost, as documented in the CMS manual update.





